Two clinical trials opened for enrollment in late 2019 at UofL Health – James Graham Brown Cancer Center for eligible men with prostate cancer. “Since the Brown Cancer Center has these clinical trials available, we can offer our prostate cancer patients the latest cancer treatments,” Scott Silva, M.D., Ph.D. , radiation oncologist, said.
Men with favorable intermediate risk prostate cancer may be eligible for the GU005 trial comparing stereotactic body radiation therapy (SBRT) to hypofractioned radiation therapy. In this trial, patients seeking radiation therapy are randomized to receive either the standard 5.5 weeks of radiation treatment (hypofractionated radiation therapy) or to receive 1.5 weeks of radiation treatment (SBRT). “We know that both types of radiation treatment offer good outcomes for prostate cancer patients, but we do not yet know if one type of radiation treatment is better than the other,” Dr. Silva said. “The purpose of the GU005 trial is to compare SBRT to hypofractionated radiation therapy to determine which is the better radiation treatment.”
Men with untreated metastatic prostate cancer may be eligible for the Southwest Oncology Group S1802 trial. The standard treatment for metastatic prostate cancer is hormone therapy and chemotherapy. In the S1802 trial, metastatic prostate cancer patients are randomized to receive either standard treatment or standard treatment plus either surgical excision of the prostate or radiation to the prostate. The goal of the S1802 trial is to determine if the addition of local treatment (surgery or radiation to the prostate) to chemotherapy and hormone therapy can improve survival in men with metastatic prostate cancer.
If interested in enrollment on these clinical trials, ask your doctor if you are an eligible candidate.
Learn about all active clinical trials at Brown Cancer Center by visiting UofLBrownCancerCenter.org/clinicaltrials.
This article was originally posted by UofL Brown Cancer Center.